^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FGFR2 M540_I541insMM

    i
    Other names: FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2
    Entrez ID:
    2263
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma. (PubMed, Target Oncol)
    Understanding the mechanisms of resistance with FGFRi is essential to understand sequencing of treatments. In this study, patients received standard chemotherapy in the first line and were fit enough to be considered for subsequent therapy with an FGFRi. Almost half of the patients become ineligible to receive further systemic therapy following progression on FGFRi. As more agents are being introduced, detailed understanding of outcomes following treatment with an FGFRi, including subsequent FGFRi, is essential.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 M540_I541insMM
    |
    Pemazyre (pemigatinib)